NGEN
NervGen Pharma Corp.Key Statistics
About NervGen Pharma Corp.
NervGen Pharma Corp. (NGEN) is an innovative biotechnology company focused on addressing unmet medical needs in the field of neurodegenerative diseases through its proprietary platform, which leverages nerve regeneration technology. The company is committed to the research and development of novel therapeutics aimed at restoring nerve function and improving patient outcomes for conditions like multiple sclerosis and spinal cord injuries. With a strategic emphasis on advancing its clinical programs and enhancing its intellectual property portfolio, NervGen is well-positioned to capitalize on the growing demand for effective treatments in the neurology sector, fostering potential long-term growth and value creation for investors.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-26.52M |
| Operating Margin | 0.00% |
| Return on Equity | -1207.00% |
| Return on Assets | -90.70% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $0.03 |
| Price-to-Book | 67.09 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -5.42 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $82.19M |
| Float | $68.03M |
| % Insiders | 20.33% |
| % Institutions | 2.06% |
Historical Volatility
Volatility is currently expanding